Scotiabank Sees Major Upside for Gain Therapeutics Stock Scotiabank has initiated coverage of Gain Therapeutics with a Sector Outperform rating and a $12 price target. Analysts cite the potential of GT-02287, a Parkinson’s treatment currently in Phase 1b trials, as a key factor. Interim trial data, expected in Q2 2025, could significantly impact the stock’s valuation.23